TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 19\~45 years in healthy volunteers~2. BMI is more than 18.5 kg/m\^2 , no more than 29.9 kg/m\^2~3. Subjects who agree to use medically accepted dual contraceptives up to two months after the last administration date of the clinical trial drug and not to provide sperm.~4. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing~Exclusion Criteria:~1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system~2. Subjects who judged ineligible by the investigator

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sequence 1 (Reference-Test) (Type: EXPERIMENTAL): Period1: HCP1306+HGP0904+HGP0608, Period 2: HCP1701
- Sequence 2 (Test-Reference) (Type: EXPERIMENTAL): Period1: HCP1701, Period 2: HCP1306+HGP0904+HGP0608

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant has one of the following genotypes:~  * Homozygous for F508del;~ * Heterozygous for F508del and a gating (F/G) mutation;~ * Heterozygous for F508del and a residual function (F/RF) mutation;~ * At least 1 other TCR CFTR gene mutation identified as responsive to ELX/TEZ/IVA and no F508del mutation~* Forced expiratory volume in 1 second (FEV1) value \>=40% and \<=90% of predicted mean for age, sex, and height for participants currently receiving CFTR protein modulator therapy; FEV1 \>=40% and \<=80% for participants not currently receiving CFTR protein modulator therapy~Key Exclusion Criteria:~* History of solid organ or hematological transplantation~* Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Pregnant or breast-feeding females~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELX/TEZ/IVA (Type: ACTIVE_COMPARATOR): Following elexacftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) run-in period of 4 weeks, participants received ELX 200 milligram (mg) once daily (qd) /TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 52 weeks.
- VX-121/TEZ/D-IVA (Type: EXPERIMENTAL): Following ELX/TEZ/IVA run-in period of 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/D-IVA 250 mg qd in the treatment period for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 10-Years Follow-up of the EXAMINATION Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who were enrolled in the EXAMINATION trial (NCT00828087).~Exclusion Criteria:~* None.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus Arm (Type: None): Everolimus Eluting Coronary Stent System
- Non-drug eluting stent Arm (Type: None): Cobalt chromium balloon-expandable stent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must be males or females 18-85 years of age who currently smoke cigarettes daily and are willing to stop smoking~Exclusion Criteria:~History of cardiovascular disease, stomach ulcer or diabetes unless physician's written approval is obtained.~Use of other forms of tobacco/nicotine containing products other than cigarettes within 30 days before baseline visit.~Use of nicotine replacement therapies or other smoking cessation medicines/non-drug therapies within 30 days before the baseline visit.~Pregnancy or intending to become pregnant.~Hypersensitivity to the product, history of alcohol or substance abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nicotine (Type: EXPERIMENTAL): Nicotine Spray
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match Nicotine spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Foley Plus Vaginal Misoprostol for Labor Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* singleton pregnancy~* vertex presentation~* unfavorable cervix(Bishop's score less than or equal to 6)~* greater than 24 weeks gestation~Exclusion Criteria:~* fetal malpresentation~* multifetal gestation~* spontaneous labor~* more than 5 uterine contractions in 10 minutes~* contraindication to prostaglandins~* non-reassuring fetal heart rate tracing~* intrauterine growth restriction~* anomalous fetus~* fetal demise~* previous cesarean delivery or other significant uterine surgery

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Foley Bulb plus Misoprostol (Type: EXPERIMENTAL): None
- Misoprostol (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting in the participating hospitals with a TIA or non-disabling stroke of atherosclerotic origin~* Randomisation within 6 months after the TIA or minor stroke~* Modified Rankin scale of 3 or less~Exclusion Criteria:~* (Contra)indication to, or intolerance to, anticoagulants, dipyridamole, or aspirin~* Disease expected to cause death within weeks or months~* Source of embolism in the heart~* Moderate or severe ischemic damage to the white matter of the brain (leukoaraiosis)~* Anemia, polycythemia, thrombocytosis, or thrombocytopenia~* Planned carotid endarterectomy~* Intracranial bleeding or cerebral tumour~* TIA or stroke caused by vasculitis, migraine, or dissection~* Severe hypertension~* Liver failure~* Pregnancy~* Chronic alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 1 month to 18 years~* ICU stay \>24 hours~* Normal seric sodium (135 - 145 mEq/L).~* Requirement of IV maintenance solutions \>80% total fluids intake~Exclusion Criteria:~* Patients with diagnoses of renal failure (serum creatinine \>1 g/dl in \<3 years old children, \>1,5 in \>3 years), hepatic failure with ascitis and portal hypertension, adrenal failure, nephrotic - nephritic syndrome, Kawasaki disease, sickle cell anemia, Syndrome of inappropriate antidiuretic hormone secretion, diabetes insipidus,metabolic disease.~* Diuretics use in the first 48 hours thereafter indicated IV solutions.~* Plasma glucose is \>200 mg%.~* Any patients requiring IV fluids therapy different that maintenance (total parenteral nutrition, hyperhydration).

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Hypotonic (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive 0.45% NaCl/5% dextrose intravenous maintenance fluids.
- Isotonic (Type: EXPERIMENTAL): Subjects in this arm will receive 0.9% NaCl/5% dextrose intravenous maintenance fluids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) physical status I and II who are to undergo elective general, urologic, orthopedic, plastic, or gynecologic surgery.~Exclusion Criteria:~* patients with age less than 18 yr or over 60 yr,~* emergency surgery,~* patients undergoing neurosurgical procedures,~* any procedure with adjunctive analgesia,~* any patient on chronic opiate use,~* females who are known to be pregnant,~* patients who had ingested psychotropic or sedative medication within one month of investigation,~* patients with personality disorders,~* weight greater than 20% of ideal, and~* any known contraindications to ketamine or propofol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: ACTIVE_COMPARATOR): As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
- Ketofol (Type: EXPERIMENTAL): As part of the induction, patients will be given 20 mL syringe of an admixture called ketofol, which combines ketamine and propofol in one syringe. The dose is weight-based such that ketamine will represent 0.75 mg/kg of the dose and propofol, 1.5 mg/kg of the dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening~* HbA1c \>or = 7% and \< or = 10%~* Fasting c-peptide \> or = 1.0 umol~* Body Mass Index \< or = 41 kg/m2~* Mean serum triglycerides \< or = 600 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Engaging Patients in Colon Cancer Screening Decisions During COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, age 45-75~* Had screening or surveillance colonoscopy delayed or cancelled from March-June 2020~Exclusion Criteria:~* Diagnostic colonoscopy~* High risk for colorectal cancer as indicated by 1 year follow up schedule~* Prior history of colon cancer~* Unable to read or write in English or Spanish~* Have already scheduled or completed a colonoscopy since restrictions were lifted

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care Arm (Type: NO_INTERVENTION): This arm will be a usual care arm. Patients may call to schedule a colonoscopy or other tests as desired.
- Shared Decision Making Arm (Type: EXPERIMENTAL): This is the intervention arm. Patients will receive a shared decision making information sheet in the mail and will be able to receive decision coaching from study staff to support selection of an option if desired.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age ≥ 18 years) patients,~* Having clinical indication for placement of a single PVC for at least 48 hours (no minimum port access during the study duration),~* Willing and able to provide informed consent.~Exclusion Criteria:~* Known allergies to CHG, PVI, isopropanol or ethanol,~* Participation to another clinical trial aimed at reducing PVC complications,~* Suspicion of bloodstream infection at catheter insertion,~* Skin injury a catheter insertion site increasing the risk of catheter infection,~* PVC inserted extremely urgently, making it impossible to comply with the protocol,~* Intravascular catheter in place within the last 2 days, or within the last 2 weeks and with local signs of catheter complication,~* Difficult catheter insertion suspected (obesity, known IV drug users, non-visible venous network after placement of a tourniquet...),~* Patients already enrolled in this study,~* Terminal or moribund patient not expected to live more than one week,~* Patients not benefiting from a Social Security scheme or not benefiting from it through a third party,~* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.~* Pregnant or breastfeeding women~* Women at age to procreate and not using effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVI et Insyte (Type: ACTIVE_COMPARATOR): Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD
- CHG et Insyte (Type: EXPERIMENTAL): Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD
- PVI et Nexiva (Type: EXPERIMENTAL): Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
- CHG et Nexiva (Type: EXPERIMENTAL): Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* multiple myeloma per International Myeloma Working Group 2014 definition~* requiring treatment for relapsed or relapsed/refractory disease~* measurable disease based on central protein assessment~* received 1 to 4 prior lines of therapy~* prior immunomodulatory agent(s) exposure~* acceptable lab values prior to randomization~Exclusion Criteria:~* primary refractory myeloma~* refractory to bortezomib~* concomitant anti-cancer therapy (other than bortezomib/dexamethasone and bisphosphonates)~* prior treatment with pan-deacetylase inhibitors~* clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months prior to randomization)~* unresolved diarrhea ≥ Common Terminology Criteria for adverse events grade 2 or presence of medical condition associated with chronic diarrhea (such as irritable bowel syndrome and inflammatory bowel disease)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A - 20 mg Panobinostat TIW (Type: EXPERIMENTAL): 20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone
- Arm B - 20 mg Panobinostat BIW (Type: EXPERIMENTAL): 20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone
- Arm C - 10 mg Panobinostat TIW (Type: EXPERIMENTAL): 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All healthy health care professionals between the ages of 18 and 60 years of age who are regular full-time employees of the MUSC Hospital, work a 10 or 12 hour work shift, and test positive for nasal vestibular S. aureus carriage within 10 days prior to their scheduled study day will be eligible to participate in the study.~Exclusion Criteria:~* Excluded from the study will be individuals exhibiting symptoms of upper respiratory disease, including chronic rhinitis/sinusitis, seasonal allergies, upper respiratory infection during the previous four weeks, have known allergy to citrus or soy oil, or are smokers. Non-smokers will be defined as those individuals who have abstained from smoking for at least one year prior to the study. Subjects must be able and agree to refrain from using prescription and non-prescription nasal spray or other nasal preparations or washes from the time of their screening up to and during their scheduled study day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Nozin® Nasal Sanitizer® (Type: EXPERIMENTAL): Non-antibiotic, alcohol-based antiseptic
- Phosphate-buffered saline (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete